James Stainer, PhD
London

James Stainer, PhD

Download PDF

London, UK | stainerjames@hotmail.com | Jamsta.in | LinkedIn | Google Scholar

Summary

PhD in AI-enabled Healthcare from UCL (viva passed October 2026, minor corrections), with a track record of building end-to-end data pipelines and forecasting systems on large, real-world data. Recent freelance work focuses on adversarial LLM-agent evaluation, using Claude Code, versioned agent skills, local proxy evals, transcript auditing, leak checks, and remote multi-model benchmark loops. Previously completed two AstraZeneca data science internships spanning large-scale data pipelines, NLP, model development, and validation. Published in Communications Biology (Nature).

Technical Skills

Languages
Python, SQL, R, Bash
Data & Infra
Data Pipelines, pandas, NumPy, Elasticsearch, Feature Engineering, SLURM, Git
ML / DL
PyTorch, TensorFlow, scikit-learn, Graph Neural Networks, NLP, Ensemble Methods
Methods
Time-series Forecasting, Statistical Inference, Bayesian Inference, Change-point Detection

Experience

Freelance AI Evaluator & Data Science Consultant

Dec 2023 – Present

Various AI Evaluation Clients

Remote
  • Delivered freelance AI evaluation and data science work across multiple projects, spanning model-output review, scientific reasoning benchmarks, failure-mode analysis, and applied AI workflows.
  • Selected current project: Adversarial LLM evaluation for expert scientific reasoning.
    • Authored adversarial evaluation tasks benchmarking frontier LLM agents on expert bioinformatics and scientific coding, with each task structured around a hidden oracle, golden answer, reference solver, grading contract, and reasoning trap.
    • Ran the task lifecycle through a versioned Claude Code agent skill, covering task scaffolding, local proxy evaluation, export, and remote multi-model benchmark calibration.
    • Audited agent transcripts to identify answer leakage, redundant reasoning shortcuts, data-access failures, and data-consistency bugs before submission.
    • Made targeted local fixes and upgrades to the agent skill’s scaffolding tooling so task generation ran end-to-end more efficiently.

Data Science Intern

Oct 2022 – Apr 2023

AstraZeneca – Centre for Genomics Research

Cambridge, UK
  • Engineered a PubMed-to-Elasticsearch data pipeline indexing 35M+ biomedical citations/abstracts from the NLM PubMed baseline, enabling fast, reliable downstream querying and relationship mining at scale.
  • Built NLP pipelines to identify, prioritise, and validate candidate drug–target–disease relationships for expert review.
  • Applied BioWordVec embeddings and semantic-similarity methods to surface relationships across disease, drug, and target ontologies.
  • Replaced broad manual search with a ranked candidate-validation workflow, significantly accelerating curation for domain scientists.

Data Science Intern

Jun 2020 – Sep 2020

AstraZeneca – Centre for Genomics Research

Cambridge, UK
  • Co-Developed the DrugnomeAI framework to predict protein-coding gene druggability across multiple therapeutic modalities.
  • Owned the full ML pipeline end to end: data collection, feature engineering, model training, validation, and benchmarking.
  • Designed ensemble ML models integrating multi-omic, structural, and functional data.
  • Used ML-based prioritisation to streamline candidate identification and accelerate expert curation.

Education

PhD in AI-enabled Healthcare

2021 – 2026

University College London (UCL)

London, UK
  • Viva passed October 2026 with minor corrections.
  • Integrated custom Graph Neural Networks to model physiological dependencies and forecast paediatric ICU patient trajectories on high-frequency 5-second time-series data.
  • Reduced forecasting error versus baseline models; designed the framework for downstream clinical decision-support integration.

MRes in AI-enabled Healthcare

2020 – 2021

University College London (UCL)

London, UK
  • Dissertation: Unsupervised ML on time-series data for clustering patient subtypes and improving decision support.

MSc in Data Science

2019 – 2020

Lancaster University

Lancaster, UK
  • Dissertation: DrugnomeAI – an ensemble framework for predicting druggability of human genes in collaboration with AstraZeneca.

BSc (Hons) Mathematics

2016 – 2019

Lancaster University

Lancaster, UK

Publications & Presentations

Journal Articles

  1. [1]A. Raies, E. Tulodziecka, J. Stainer et al. “DrugnomeAI is an ensemble machine-learning framework for predicting druggability of candidate drug targets.” Communications Biology (Nature), 2022.

Conference Presentations

  1. [2]J. Stainer et al. Poster presentation at the IEEE Engineering in Medicine and Biology Society (EMBS) Conference, 2024.
  2. [3]J. Stainer et al. Poster presentation at the IEEE International Conference on Biomedical and Health Informatics (BHI), 2024.

Selected Projects

Multivariate ICU Forecasting with StemGNN

PhD Thesis at UCL & Great Ormond Street Hospital
  • Incorporated a PyTorch StemGNN model to jointly forecast heart rate and blood pressure from 5-second paediatric ICU bedside-monitor data at Great Ormond Street Hospital.
  • Built the full clinical time-series pipeline: filtering from 4,120 raw admissions to 364 high-quality patients, age-aware normalisation, missing-data handling, outlier detection, and sliding-window segmentation across ~12.5M observations.
  • Modelled HR–BP dependencies as a learned graph and benchmarked performance against baselines.
  • Achieved 2.30% / 3.49% MAPE (HR / BP) on 5-minute-ahead forecasts at 1-minute resolution, outperforming ARIMA (2.82% / 3.85%) and a persistence baseline.

DrugnomeAI – Gene Druggability Prediction

GitHub | Web App
  • Published ML framework predicting druggability across all 19,846 human protein-coding genes; integrated 324 features from 15 sources and outperformed three published benchmarks.
  • Developed a stochastic semi-supervised ML framework that scores druggability likelihood for all protein-coding genes in the human exome.
  • Top-ranked genes were significantly enriched for targets already in clinical development (p < 1 × 10−308) and for genome-wide significant hits in UK Biobank PheWAS of 450K exomes.
  • Built specialised models stratified by drug modality (small molecule, antibody, PROTAC) and therapeutic area, outperforming three published benchmarks on independent validation sets.
EmailLinkedInScholar